Technology
Health
Pharmaceutical

Tyme Technologies

$1.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.80%) As of 3:29 PM EDT today
-$0.01 (-0.80%) Today

Why Robinhood?

You can buy or sell TYME and other stocks, options, ETFs, and crypto commission-free!

About TYME

Tyme Technologies, Inc. Common Stock, also called Tyme Technologies, is a biotechnology company, which engages in the development and commercialization of cancer therapies. Read More It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in New York, NY.

Employees
15
Headquarters
New York, New York
Founded
2011
Market Cap
129.93M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.91M
High Today
$1.29
Low Today
$1.22
Open Price
$1.25
Volume
119.30K
52 Week High
$4.64
52 Week Low
$0.92

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Biotechnology
Medical
2015 IPO
US

TYME News

MarketWatchJul 5

Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study

1,194

TYME Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, Pre-Market

More TYME News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.